Unlike many other oncoproteins that promote cellular transformation following activating mutations (e.g., EGFR, Ras or B-Raf), Myc-driven cancers are virtually always due to its overexpression (e.g., following gene amplification) or deregulation (e.g., via tonic signaling from upstream growth pathways, or impaired degradation). This evidence concerns the gene MYC and cancer.